To hear about similar clinical trials, please enter your email below
Trial Title:
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT ID:
NCT06142188
Condition:
Lymphoma, B-Cell
Large B-cell Lymphoma
Follicular Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, B-Cell
Hematologic Neoplasms
Conditions: Keywords:
Relmacabtagene Autoleucel
Chimeric antigen receptor T cells
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Biological
Intervention name:
Relmacabtagene Autoleucel
Description:
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Arm group label:
Relmacabtagene Autoleucel
Other name:
JWCAR029
Summary:
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of
adult patients with hematologic malignancies in real-world
Detailed description:
The purpose of this study is to observationally evaluate the efficacy and safety data of
Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for
up to 15 years after infusion. The treating physician will determine the most appropriate
diagnostic and therapeutic regimen for the patient based on clinical practice. No
therapeutic intervention will be administered to patients in this study.
Criteria for eligibility:
Study pop:
Hematologic Malignancies
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Signed informed consent
2. Patients who have been treated with Relma-cel, including those who have received
off-label products;
3. If previously enrolled in another clinical study, they must have completed follow-up
in the previous study, or have withdrawn or lost follow-up in the previous study.
Exclusion Criteria:
1.Patients who have been treated with Relma-cel and then have been treated with other
CAR-T products.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Beijing Cancer Hospital
Address:
City:
Beijing
Zip:
100010
Country:
China
Contact:
Last name:
Yuqing Song, PhD
Facility:
Name:
Peking University International Hospital
Address:
City:
Beijing
Zip:
100010
Country:
China
Contact:
Last name:
Xinjian Liu
Start date:
December 28, 2023
Completion date:
December 31, 2038
Lead sponsor:
Agency:
Shanghai Ming Ju Biotechnology Co., Ltd.
Agency class:
Industry
Source:
Shanghai Ming Ju Biotechnology Co., Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06142188
